Akums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals is an Indian contract development and manufacturing organization serving pharmaceutical companies through formulation development, drug manufacturing, and related technical services.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Haridwar, Uttarakhand. Founded in 2004 by Sanjeev Jain and Sandeep Jain, the company serves domestic pharmaceutical businesses as well as multinational customers. Its principal role in the pharmaceutical value chain is to develop and manufacture finished dosage forms for other companies, rather than relying exclusively on a consumer-facing portfolio of proprietary brands. The company's capabilities span formulation development, technology transfer, commercial production, quality-control support, packaging, and related pharmaceutical manufacturing services. Its portfolio includes tablets, hard-gelatin capsules, soft gels, dry syrups, liquid oral medicines, topical products, and parenteral products such as vials, ampoules, eye drops, and form-fill-seal presentations. Akums also operates facilities for active pharmaceutical ingredient production and research and development centers in India. These capabilities allow it to support customer projects across development, scale-up, regulatory manufacturing, and supply. Akums has built a manufacturing network comprising multiple formulation plants and two API facilities. Some Haridwar units have obtained international GMP certifications, supporting the company's stated objective of serving regulated and export markets. The company has also pursued product and intellectual-property development, including a manufacturing and commercialization licence for bempedoic acid, a patent relating to an extended-release doxylamine and pyridoxine combination, and a patent for a dual-release gastro-resistant composition. In 2026, it received United Kingdom regulatory approval to market rivaroxaban, an anticoagulant. The business expanded through both organic development and transactions. In 2020, Quadria Capital invested Rs 500 crore in the company. In April 2022, Akums acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited. These developments strengthened its production footprint and supported its transition toward a larger, more diversified CDMO platform. Akums became a publicly traded company on 6 August 2024, with shares listed on the Bombay Stock Exchange and the National Stock Exchange of India. Public-company status increased the amount of information available about its operations and strategic activity, although detailed customer-level revenue, product-level sales, and complete geographic revenue data should be verified through current company filings and exchange disclosures. Its present positioning is that of an Indian, multi-dosage-form pharmaceutical manufacturing partner with domestic scale, development capabilities, and growing access to regulated international markets.
History
Akums Drugs and Pharmaceuticals was established in 2004 by Sanjeev Jain and Sandeep Jain in India. Both founders are identified as managing directors, and the company developed around pharmaceutical manufacturing and contract supply rather than a single consumer-oriented medicine brand. Over time, it expanded into a broader contract development and manufacturing organization, serving Indian pharmaceutical companies and multinational customers. Its operating model combines formulation development with production of finished pharmaceutical products. Akums' manufacturing activities cover oral solid forms such as tablets and capsules, soft gels, dry syrups, liquid oral medicines, topical preparations, and sterile or other parenteral presentations. The company also has two facilities for active pharmaceutical ingredients and four research and development centers in India. This combination of development, API, dosage-form, and packaging capabilities reflects the increasing outsourcing of pharmaceutical production to specialized Indian manufacturers. The company received a reported Rs 500 crore investment from Quadria Capital in 2020. In April 2022, it acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited. During the same year, it obtained a licence to manufacture and commercialize bempedoic acid. Its regulatory reach also broadened when two Haridwar units received European GMP certification: one for solid oral products, including tablets and hard-gelatin capsules, and another for large- and small-volume parenterals, including vials, ampoules, eye drops, and form-fill-seal products. Akums entered the Indian public markets on 6 August 2024, when it became listed on the Bombay Stock Exchange and the National Stock Exchange. Listing marked a significant change in its corporate profile, providing public-market access and subjecting the company to continuing exchange and regulatory disclosure requirements. In 2025, the company continued developing its intellectual-property and international-compliance position. It received a patent for an extended-release combination of doxylamine and pyridoxine for the management of nausea and vomiting in pregnancy. It also obtained a 20-year patent for a dual-release gastro-resistant composition, with the patent effective from 19 November 2022. During July and September, facilities in Haridwar received additional GMP certifications, including certification connected with Brazil's health regulator and the Eurasian Economic Union for a hormonal-therapy unit. In January 2026, two Haridwar facilities received European Union GMP certification from the Bulgarian Drug Agency. The following month, Akums received approval from the UK's Medicines and Healthcare products Regulatory Agency to market rivaroxaban. These certifications and approvals indicate an effort to extend the company's manufacturing and product-access capabilities beyond India. Public sources do not establish a complete chronology of every plant expansion, customer contract, product registration, or financial result; those matters require confirmation from current corporate filings and regulator records.
- 2026
European Union GMP certification
[1]Two Haridwar facilities received EU GMP certification issued by the Bulgarian Drug Agency.
- 2026
UK rivaroxaban approval
[1]The UK MHRA approved Akums to market rivaroxaban in the United Kingdom.
- 2025
Doxylamine-pyridoxine patent
[1]Akums received a patent for an extended-release combination formulation of doxylamine and pyridoxine.
- 2025
Dual-release composition patent
[1]The company received a 20-year patent for a dual-release gastro-resistant composition.
- 2024
Public listing
[1]Akums became publicly listed on the Bombay Stock Exchange and the National Stock Exchange on 6 August.
- 2022
Manufacturing facility acquisition
[1]Akums acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited.
- 2022
Bempedoic acid licence
[1]The company received authorization to manufacture and commercialize bempedoic acid.
- 2020
Quadria Capital investment
[1]Quadria Capital invested a reported Rs 500 crore in Akums.
- 2004
Company established
[1]Sanjeev Jain and Sandeep Jain established Akums Drugs and Pharmaceuticals in India.
Products and positioning
Indian multi-dosage-form pharmaceutical CDMO and finished-drug manufacturer serving domestic and multinational pharmaceutical companies.
Finished pharmaceutical dosage form
Tablets
Tablets are a major oral-solid dosage form manufactured by Akums for its own production activities and customer programs. The company's support can include formulation development, process scale-up, commercial manufacture, testing, and packaging. Individual active ingredients, brands, and therapeutic applications vary by customer and regulatory market.
Finished pharmaceutical dosage form
Hard-gelatin capsules
Hard-gelatin capsules form part of Akums' oral-solid manufacturing capabilities. They can be produced under contract for pharmaceutical companies that outsource formulation and finished-dose manufacturing. Akums has identified a European-GMP-certified unit associated with solid oral products, including capsules.
Finished pharmaceutical dosage form
Soft gels
Soft gels are among the dosage forms included in Akums' pharmaceutical production portfolio. They are typically used for formulations requiring encapsulation of liquid or semi-solid fills. Specific products and customer brands are not fully identified in the available reference material.
Finished pharmaceutical dosage form
Dry syrups
Dry syrups are powdered or granulated medicines intended for reconstitution before administration. Akums manufactures this dosage form as part of its contract and finished-pharmaceutical activities, with formulation, production, testing, and packaging determined by the relevant customer and product registration.
Finished pharmaceutical dosage form
Liquid oral formulations
Liquid oral products, including oral solutions and syrups, are part of Akums' multi-dosage-form manufacturing range. These products support customers that need non-solid presentations and may require specialized filling, stability testing, and packaging. The available sources do not specify a single flagship liquid formulation.
Sterile and injectable pharmaceutical products
Parenteral products
Akums' parenteral capabilities include large- and small-volume products such as vials, ampoules, eye drops, and form-fill-seal formulations. A Haridwar unit associated with these products received European GMP certification, supporting manufacture for markets with regulated quality requirements.
Pharmaceutical raw materials
Active pharmaceutical ingredients
Akums operates two facilities for producing active pharmaceutical ingredients. API manufacturing complements its finished-dose and CDMO operations by adding upstream production capability, although the available reference does not provide a complete list of APIs or identify the proportion of revenue generated by this activity.
Anticoagulant medicine · 2026
Rivaroxaban
Rivaroxaban is an anticoagulant that Akums received UK MHRA approval to market in February 2026. The available material identifies the regulatory authorization but does not specify the product's brand name, commercial launch date, dosage presentation, or financial contribution.
Brand decisions
2026
Obtain UK authorization for rivaroxabanProduct launchBackground
Akums was expanding its access to regulated international pharmaceutical markets.
Action taken
The UK MHRA approved the company to market rivaroxaban in the United Kingdom.
Aftermath
The approval created a regulatory pathway for UK commercialization of the anticoagulant, although the launch timing and commercial scale are not specified.
2024
Enter the public marketsStrategyBackground
Akums had expanded into a multi-facility pharmaceutical manufacturing and CDMO business and sought public-market access.
Action taken
The company completed its public listing on 6 August 2024 on the Bombay Stock Exchange and the National Stock Exchange of India.
Aftermath
Akums became a publicly traded pharmaceutical company subject to ongoing exchange and regulatory disclosure requirements.
2022
Acquire a manufacturing facility from Ankur DrugsM&ABackground
Akums sought to expand its pharmaceutical manufacturing footprint and production capacity.
Action taken
The company acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited in April 2022.
Aftermath
The transaction added manufacturing infrastructure to Akums' broader CDMO and finished-dose platform; detailed capacity and financial effects are not specified in the available source.
Recent events
- 2026
Two Akums facilities receive European Union GMP certification[1]
Regulation
Two Haridwar facilities received European Union GMP certification issued by the Bulgarian Drug Agency.
- 2026
Akums receives UK approval for rivaroxaban[1]
Product launch · Regulation
The United Kingdom Medicines and Healthcare products Regulatory Agency approved Akums to market rivaroxaban, an anticoagulant, in the UK.
- 2025
Akums receives patent for extended-release doxylamine and pyridoxine formulation[1]
Other
The company received a patent for an extended-release combination formulation of doxylamine and pyridoxine intended for management of nausea and vomiting during pregnancy.
- 2025
Akums receives additional international GMP certifications[1]
Regulation
Facilities in Haridwar received GMP certifications during July and September, including certification associated with Brazil's health regulator and EAEU certification for a hormonal-therapy unit.
- 2025
Akums receives patent for dual-release gastro-resistant composition[1]
Other
In November, the company was granted a 20-year patent under India's Patents Act, 1970, for a dual-release gastro-resistant composition, effective from 19 November 2022.
- 2024
Akums becomes publicly listed in India[1]
Other
Akums went public on 6 August 2024, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange of India.
- 2022
Akums acquires a manufacturing facility from Ankur Drugs and Pharmaceuticals[1]
M&A
Akums acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited in April, expanding its production infrastructure.
- 2022
Akums receives authorization for bempedoic acid manufacture and commercialization[1]
Product launch · Regulation
The company received a licence in May to manufacture and commercialize bempedoic acid, a medicine used to lower cholesterol.
- 2020
Quadria Capital invests Rs 500 crore in Akums[1]
M&A · Other
Quadria Capital made a reported Rs 500 crore investment in Akums, supporting the company's expansion as a pharmaceutical manufacturing and CDMO platform.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/akums-drugs-and-pharmaceuticals · Editorial policy · How profiles are compiled